These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 10251227)
21. The patient package insert--health care provider's friend or foe? Hirsh HL Nurs Homes; 1979; 28(4):24-5. PubMed ID: 10283734 [No Abstract] [Full Text] [Related]
22. Proposed NSAID package insert labeling. Food and Drug Administration U.S. Public Health Service J Pain Palliat Care Pharmacother; 2006; 20(1):49-55. PubMed ID: 16687359 [TBL] [Abstract][Full Text] [Related]
23. The medicolegal significance of the package insert. Hirsh HL Conn Med; 1978 Dec; 42(12):785-8. PubMed ID: 720048 [No Abstract] [Full Text] [Related]
24. Drug use, the package insert, and the practice of medicine. Roth SH Arch Intern Med; 1982 May; 142(5):871-2. PubMed ID: 7082110 [No Abstract] [Full Text] [Related]
25. Emergency contraception: still not too late. Wellbery C Am Fam Physician; 2000 Nov; 62(10):2222, 2225-6. PubMed ID: 11126849 [No Abstract] [Full Text] [Related]
26. FDA acts on estrogen, progestin labeling. FDA Consum; 1977 Nov; 11(9):3. PubMed ID: 10305006 [No Abstract] [Full Text] [Related]
27. The medicolegal significance of the package insert. Hirsh HL J Fam Pract; 1977 Jun; 4(6):1141-3. PubMed ID: 874441 [No Abstract] [Full Text] [Related]
28. The medicolegal significance of the package insert. Hirsh HL Med Trial Tech Q; 1976; 23(2):143-50. PubMed ID: 1004155 [No Abstract] [Full Text] [Related]
29. Developing drug information for patients. Hecht A FDA Consum; 1977 Sep; 11(7):16-9. PubMed ID: 10304999 [No Abstract] [Full Text] [Related]
30. Package insert-stuffer, guide or autocrat? Can Med Assoc J; 1968 Aug 24-31; 99(8):377-9. PubMed ID: 4952400 [No Abstract] [Full Text] [Related]
31. The practice of anesthesiology and the package insert: decision-making regarding drug use in anesthesiology. White PF; Watcha MF Anesth Analg; 1993 May; 76(5):928-30. PubMed ID: 8484546 [No Abstract] [Full Text] [Related]
32. Is the FDA packing a surprise for you? Chapman S Leg Aspects Med Pract; 1979 Nov; 7(11):35-8. PubMed ID: 263195 [No Abstract] [Full Text] [Related]
33. Prescription drugs; revocation of final guideline patient package inserts and withdrawal of draft guideline patient package inserts--Food and Drug Administration. Notice. Fed Regist; 1982 Sep; 47(173):39249-50. PubMed ID: 10258155 [TBL] [Abstract][Full Text] [Related]
34. Progestational drug products for human use; requirements for labeling directed to the patient. Food and Drug Administration, HHS. Final rule. Fed Regist; 1999 Nov; 64(220):62110-2. PubMed ID: 11010691 [TBL] [Abstract][Full Text] [Related]
35. Drug labeling and promotion: evolution and application of regulatory policy. Hayes TA Food Drug Law J; 1996; 51(1):57-73. PubMed ID: 11794353 [No Abstract] [Full Text] [Related]
36. On narrowing the patient-doctor communications gap. FDA Consum; 1982 May; 16(4):19-21. PubMed ID: 10309635 [No Abstract] [Full Text] [Related]
37. FDA notifications. Updates made to Reyataz package insert. AIDS Alert; 2008 Oct; 23(10):116-7. PubMed ID: 18935687 [No Abstract] [Full Text] [Related]
38. Mandatory PPIs to begin in 1981; APhA issues strong objections. Small WE Am Pharm; 1980 Nov; NS20(11):10-1. PubMed ID: 7457342 [No Abstract] [Full Text] [Related]
39. Power of the package insert. Chayet NL N Engl J Med; 1967 Dec; 277(23):1253-4. PubMed ID: 6072669 [No Abstract] [Full Text] [Related]